Table 2 Comparison of regression and recurrence rate between patients with retinopathy of prematurity received intravitreal Bevacizumab (IVB) and intravitreal Aflibercept (IVA)
From: Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity
Parameter | Level | Total | Type of treatment | p‡ | |
|---|---|---|---|---|---|
IVB | IVA | ||||
Regression | Number (%) | 854 (96.1%) | 830 (96.0%) | 24 (100.0%) | 0.023 |
Estimated Median (days) (95% CI)† | 10.0 (9.2 to 10.8) | 14.0 (9.2 to 18.8) | |||
Mean observed time (days) ± SD ¥ | 14 ± 10 | 22 ± 15 | |||
Median observed time (days) (range) ¥ | 10 (1 to 64) | 16 (6 to 57) | |||
Recurrence | Number (%) | 47 (5.5%) | 34 (3.9%) | 14 (58.3%) | < 0.001 |
Estimated Median (days) (95% CI)† | NA | 96.0 (76.3 to 115.7) | |||
Mean observed time (days) ± SD ¥ | 47 | 104 | |||
Median observed time (days) ¥ | 23 | 92 | |||